Search

Your search keyword '"Chris Nicholas Hurt"' showing total 3 results
Start Over Author "Chris Nicholas Hurt" Journal annals of oncology
3 results on '"Chris Nicholas Hurt"'

1. CCL5 is associated with poor prognosis in locally advanced pancreatic cancer (LAPC): biomarker analysis from the randomised phase II SCALOP trial

Author

Catrin Cox, S. Mukherjee, Chris Nicholas Hurt, Frances Willenbrock, A Sabbagh, Eric O'Neill, R. Owens, C. Wilhelm-benartzic, Tim Maughan, and Aswin George Abraham

Subjects
Oncology, medicine.medical_specialty, Poor prognosis, business.industry, Internal medicine, medicine, Hematology, Biomarker Analysis, business, CCL5, Locally advanced pancreatic cancer
Published
2019
Full Text
View/download PDF

2. P-222 Analysis of tumour contours and radiotherapy planning of 'on-trial' patients undergoing chemoradiotherapy (CRT) in SCALOP trial: does pre-trial Radiotherapy Quality Assurance (RTQA) improve the quality of 'on-trial' radiotherapy?

Author

John Staffurth, S. Mukherjee, Emiliano Spezi, Emmanouil Fokas, G. Joseph, Lisette Sheena Nixon, K. Chu, Chris Nicholas Hurt, Neel Patel, and Ross A. Abrams

Subjects
Oncology, medicine.medical_specialty, Gross tumour volume, business.industry, medicine.medical_treatment, Induction chemotherapy, Hematology, TS, Gemcitabine, RC0254, Radiation therapy, Capecitabine, Abstracts, Internal medicine, medicine, Radiology, business, Quality assurance, Chemoradiotherapy, medicine.drug
Abstract

The SCALOP trial tested the safety and efficacy of gemcitabine (Gem) versus capecitabine (Cap) based CRT following induction chemotherapy and showed that GemRT was associated with greater toxicity and worse survival1. The evaluation of investigator-delineated volumes and plan assessment from the pre-trial RTQA program using a single benchmark case showed considerable variation in gross tumour volume (GTV) outlining but no major deviations in other aspects of RT planning.

Published
2016
Full Text
View/download PDF

3. O-003 Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)

Author

G. Radhakrishna, Ruby Ray, John Staffurth, Tim Maughan, John Bridgewater, Tom Crosby, C Jephcott, Harpreet Wasan, Gareth Griffiths, S. Mukherjee, Stephen Falk, R. Roy, Chris Nicholas Hurt, Sebastian Cummins, Ross A. Abrams, Alec McDonald, and G. Joseph

Subjects
Oncology, medicine.medical_specialty, business.industry, Phases of clinical research, Hematology, medicine.disease, Outcome (game theory), Gemcitabine, Locally advanced pancreatic cancer, Capecitabine, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Pancreatic cancer, Internal medicine, medicine, 030211 gastroenterology & hepatology, Multi centre, business, medicine.drug
Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results